Shockwave Medical is a commercial-stage medical device innovator that has developed a novel Intravascular Lithotripsy (IVL) system for disrupting vascular calcium. Founded in 2009 and now part of Johnson & Johnson MedTech, the company's technology addresses a significant unmet need in interventional cardiology and vascular medicine, offering a safer and more predictable alternative to existing treatments for calcified lesions. With established products in coronary and peripheral markets and a clear reimbursement pathway, Shockwave is positioned for continued growth in a large and expanding global market.
Cardiovascular
Technology Platform
Intravascular Lithotripsy (IVL) - uses sonic pressure waves to fracture vascular calcium.
Funding History
4
Total raised:$130M
IPOUndisclosedUndisclosed
Series C$60MFrazier Healthcare Partners
Series B$35MFrazier Healthcare Partners
Series A$35MFrazier Healthcare Partners
Opportunities
The global rise in cardiovascular disease and calcified lesions presents a large and growing addressable market.
Integration with Johnson & Johnson provides immense resources for global commercial expansion, accelerated R&D, and exploration of new vascular indications.
The technology's strong clinical data supports continued guideline inclusion and favorable reimbursement, driving deeper market penetration.
Risk Factors
Competition from other large medical device companies developing alternative calcium-modifying technologies poses a long-term threat to market share and pricing.
Successful integration into the Johnson & Johnson corporate structure is critical to maintain the innovative culture and agility that fueled Shockwave's initial success.
Ongoing need to secure and maintain favorable reimbursement policies in existing and new geographic markets.
Competitive Landscape
Shockwave's IVL technology competes with traditional methods for treating calcified lesions, including high-pressure balloons, scoring/cutting balloons, rotational/orbital atherectomy, and laser atherectomy. Its primary competitive advantage is a superior safety profile and procedural simplicity. As the first-mover in commercial IVL, it holds a significant lead, but large rivals like Boston Scientific, Medtronic, and Abbott could develop or acquire competing lithotripsy platforms.
